Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Primary Cell-based Therapeutics, Stem Cell & Progenitor Cell-based Therapeutics), By Therapeutic Category (Dermatology, Musculoskeletal), By Region, And Segment Forecasts, 2024

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Primary Cell-based Therapeutics, Stem Cell & Progenitor Cell-based Therapeutics), By Therapeutic Category (Dermatology, Musculoskeletal), By Region, And Segment Forecasts, 2024 - 2030


Regenerative Medicine Market Growth & Trends

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson’s disease treatment. This approval was expected to expand the company’s offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights
  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2023 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2023 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Information Procurement
1.3.1. Primary Others
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Market Model
1.7. Objectives
1.7.1. Objective 1
1.7.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Presence of a strong pipeline and a large number of clinical trials
3.3.2. High economic impact of regenerative medicine
3.3.3. Emerging applications of gene therapy in regenerative medicine
3.3.4. Increasing government & private funding to support the development of regenerative medicine
3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.4. Market Restraint Analysis
3.4.1. High cost of treatment
3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Global Regenerative Medicine Market: Product Movement Analysis
4.2. Therapeutics
4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
4.2.2. Primary Cell-Based Therapeutics
4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
4.2.2.2. Dermatology
4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
4.2.2.3. Musculoskeletal
4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
4.2.2.4. Surgical
4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
4.2.2.5. Dental
4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
4.2.2.6. Others
4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
4.2.3. Stem Cell & Progenitor Cell-based therapeutics
4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
4.2.3.2. Autologous
4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
4.2.3.3. Allogenic
4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
4.2.3.4. Others
4.2.3.5. Others Market, 2018 - 2030 (USD Million)
4.2.4. Cell-based Immunotherapies
4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
4.2.5. Gene Therapies
4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
4.3. Tools
4.3.1. Tools Market, 2018 - 2030 (USD Million)
4.4. Banks
4.4.1. Banks Market, 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Services Market, 2018 - 2030 (USD Million)
Chapter 5. Therapeutic Category Business Analysis
5.1. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
5.2. Dermatology
5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
5.3. Musculoskeletal
5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
5.4. Immunology & Inflammation
5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
5.5. Oncology
5.5.1. Oncology Market, 2018 - 2030 (USD Million)
5.6. Cardiovascular
5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
5.7. Ophthalmology
5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
5.8. Others
5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Global Regenerative Medicine Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. Target Disease Prevalence
6.2.2.5. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Target Disease Prevalence
6.2.3.5. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. Target Disease Prevalence
6.3.2.5. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Target Disease Prevalence
6.3.3.5. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Target Disease Prevalence
6.3.4.5. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Target Disease Prevalence
6.3.5.5. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Target Disease Prevalence
6.3.6.5. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Target Disease Prevalence
6.3.7.5. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Target Disease Prevalence
6.3.8.5. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Target Disease Prevalence
6.3.9.5. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Target Disease Prevalence
6.4.2.5. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Target Disease Prevalence
6.4.3.5. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Target Disease Prevalence
6.4.4.5. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Target Disease Prevalence
6.4.5.5. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Target Disease Prevalence
6.4.6.5. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Target Disease Prevalence
6.4.7.5. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Target Disease Prevalence
6.5.2.5. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Target Disease Prevalence
6.5.3.5. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Target Disease Prevalence
6.5.4.5. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Target Disease Prevalence
6.6.2.5. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Target Disease Prevalence
6.6.3.5. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Target Disease Prevalence
6.6.4.5. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Target Disease Prevalence
6.6.5.5. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market/Position Share Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. AstraZeneca plc.
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. F. Hoffmann-La Roche Ltd.
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Integra Lifesciences Corp.
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Astellas Pharma, Inc.
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Cook Biotech, Inc.
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Bayer AG
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Pfizer, Inc.
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Merck KGaA
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Abbott
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Vericel Corp.
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Novartis AG
7.4.11.1. Overview
7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GlaxoSmithKline
7.4.12.1. Overview
7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings